Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases per 100,000 people. Despite ...

Today, on IgA Nephropathy Awareness Day, the American Kidney Fund (AKF) proudly announces the creation of new educational resources for “A Step Ahead of IgA Nephropathy,” its newly updated educational ...

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy. Otsuka is hoping to file for approval of its ...

The IgA nephropathy treatment approach aims to reduce proteinuria, manage blood pressure, and slow the progression of the disease. First-line IgA nephropathy treatment typically involves ...

(MENAFN- GlobeNewsWire - Nasdaq) ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Today, on IgA Nephropathy Awareness Day, the American Kidney Fund (AKF) proudly announces the creation of new ...